**TABLES**

**Table 1- RESULTS - Demographic Data**

|  |  |
| --- | --- |
| **Parameters****Table1.** Summary of patients demographic data  | **Study eye** |
| Number | 13 patients 13 eyes |
| Final age, years | 61.9 ± 15.8 |
| Gender (male:female) | 2:11 |
| Follow-up period (months) | 96.62 ± 5.4 |
| Spherical equivalent (D) | -15.9 ± 5,7 |
| Pseudophakia | 2 |
| Previous PDT  | 8 |

***PDT*** photodynamic therapy with verteporfin.

**Table 2- RESULTS - Progression of Visual Acuity**

|  |  |  |
| --- | --- | --- |
| **Number of letters****Table2.** Visual acuity outcomes in the end of *follow-up*  | **n (eyes)** | **% (eyes)** |
| <-15 | 2 | 15.4 |
| -15 to -5 | 5 | 38.5 |
| -5 to + 5 | 2 | 15.4 |
| +5 to +15 | 1 | 7.7 |
| >+15 | 3 | 23.1 |
| VA decline | 7 | 53.8 |
| VA improvement | 6 | 46.2 |

***VA*** Visual acuity.

**DIAGRAMS**

**Diagram 1- RESULTS - Progression of Visual Acuity**

**Diagram1.** Best Corrected Visual Acuity (BCVA) annually during *follow-up.*

**Diagram 2- RESULTS - Central macular thickness**

**Diagram2.** Central macular thickness (µm) evolution during *follow-up.*